SEC Form 4
Generate Biomedicines, Inc. (GENB) insider trading
In the 12 months to Nov 19, 2026, one GENB insider reported open-market sales of $200.7K across 2 filings; 5 insiders bought $150.3M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $200.7K
- 2 filings · 1 insider
- Open-market purchases
- $150.3M
- 6 filings
- Pre-arranged sales (10b5-1)
- 2 of 2
- All $200.7K sold was pre-arranged
Who traded GENB, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
GENB daily close from Feb 27, 2026 to Nov 18, 2026, between $9.84 and $20.38, last $10.38. 2 sale and 6 purchase filings by 6 insiders, marked at their filing dates. Noubar Afeyan, Director: bought $150.0M across 2 filings, first filed Mar 2, 2026, last Mar 2, 2026. Michael Nally, Chief Executive Officer: bought $240.0K across 1 filing, first filed Mar 6, 2026, last Mar 6, 2026. Frances Arnold, Director: sold $200.7K across 2 filings, first filed Sep 3, 2026, last Nov 4, 2026. Jane L. Mendillo, Director: bought $24.0K across 1 filing, first filed Mar 2, 2026, last Mar 2, 2026. Jason Silvers, President & CFO: bought $24.0K across 1 filing, first filed Mar 2, 2026, last Mar 2, 2026. Beth Grous, Chief People Officer: bought $4.8K across 1 filing, first filed Mar 2, 2026, last Mar 2, 2026.
Largest mark · tap a row for others
Noubar Afeyan · Director
Filing 1 of 2 within a week · $150,000,000 total
Purchase $75,000,000
4,687,500 shares at $16.00 avg
Filed Mar 2, 2026
Close on filing date $12.17
Noubar Afeyan · Director
Director
$150.0M boughtMichael Nally · Chief Executive Officer
Chief Executive Officer
$240.0K boughtFrances Arnold · Director
Director
$200.7K soldJane L. Mendillo · Director
Director
$24.0K boughtJason Silvers · President & CFO
President & CFO
$24.0K boughtBeth Grous · Chief People Officer
Chief People Officer
$4.8K boughtOpen-market trades
8 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Noubar Afeyan | Director | — | $150.0M | 2 | — | |
| Michael Nally | Chief Executive Officer | — | $240.0K | 1 | — | |
| Frances Arnold | Director | $200.7K | — | 2 | 100% of sales | |
| Jane L. Mendillo | Director | — | $24.0K | 1 | — | |
| Jason Silvers | President & CFO | — | $24.0K | 1 | — | |
| Beth Grous | Chief People Officer | — | $4.8K | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Frances Arnold Director | SalePre-arranged (10b5-1) | 11,409 | $16.19 | $184.7K | 220,063 | |
traded | Frances Arnold Director | SalePre-arranged (10b5-1) | 1,000 | $16.00 | $16.0K | 231,472 | |
traded | Michael Nally Chief Executive Officer | Purchase | 20,000 | $12.00 | $240.0K | 572,707 | |
traded | Noubar Afeyan Director | Purchase | 4,687,500 | $16.00 | $75.0M | Multiple accounts | |
traded | Jane L. Mendillo Director | Purchase | 1,500 | $16.00 | $24.0K | 1,500 | |
traded | Noubar Afeyan Director | Purchase | 4,687,500 | $16.00 | $75.0M | Multiple accounts | |
traded | Jason Silvers President & CFO | Purchase | 1,500 | $16.00 | $24.0K | Multiple accounts | |
traded | Beth Grous Chief People Officer | Purchase | 300 | $16.00 | $4.8K | 300 |
GET /stocks/filings/vX/form-4?tickers=GENB&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"GENB"
],
"issuer_cik": "0002100782",
"owner_cik": "0001665419",
"accession_number": "0001193125-26-447199",
"form_type": "4",
"filing_date": "2026-11-04",
"period_of_report": "2026-10-29",
"issuer_name": "Generate Biomedicines, Inc.",
"issuer_trading_symbol": "GENB",
"owner_name": "ARNOLD FRANCES",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-29",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 11409,
"transaction_price_per_share": 16.1919,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 220063,
"transaction_value": 184733.3871,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
},
{
"tickers": [
"GENB"
],
"issuer_cik": "0002100782",
"owner_cik": "0001665419",
"accession_number": "0001193125-26-381875",
"form_type": "4",
"filing_date": "2026-09-03",
"period_of_report": "2026-09-01",
"issuer_name": "Generate Biomedicines, Inc.",
"issuer_trading_symbol": "GENB",
"owner_name": "ARNOLD FRANCES",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-01",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1000,
"transaction_price_per_share": 16.002,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 231472,
"transaction_value": 16001.999999999998,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.01 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 12 records
- Other12 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Generate Biomedicines, Inc.'s CEO sold stock?
No. Michael Nally (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is GENB’s insider data?
These are GENB Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track GENB insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for GENB every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.